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Background: Antimicrobial resistance to cephalosporin, penicillin and aztreonam is mediated by Extended-Spectrum 
Beta-Lactamases (ESBL) via hydrolysis of antibiotics. The most common bacteria associated with ESBL among the 
Enterobacteriaceae are Escherichia coli and Klebsiella pneumonia. Pathogenic Escherichia coli is associated with 
diarrhoea affecting mostly elderly, children under five years and the immunocompromised. There are a number of 
antibiotic regimens for treatment among them cephalosporins. There is reported increase in microbial resistance to 
cephalosporin use and the resistance is mediated by either TEM or SHV genes.  
Objective: To investigate the prevalence of ESBL-producing E. coli and Klebsiella pneumonia from patients presenting 
with diarrhea in Machakos District Hospital, Kenya. 
Methods: Bacterial isolates were identified to species level by biochemical methods and tested for sensitivity to 
twelve different antibiotics including cephalosporins, aminoglycosides and quinolones. Those resistant to 
cephalosporins with a zone diameter of ≤20 mm were tested phenotypically for Extended Spectrum Beta Lactamase 
(ESBL) phantom development and confirmed by MicroScan. Resistant strains to cephalosporin were further tested for 
presence and frequency of TEM and SHV genes. 
Results: Out of the 200 K. pneumonia and 100 E.coli tested, 18 (6%) were positive for ESBL production 
phenotypically. These 18 (100 %) isolates demonstrated phantom phenomena phenotypically. Eight (4%) and 2 (1%) 
of the 200 K. pneumonia isolates had TEM and SHV resistant genes, respectively. There were 5 (5%) TEM and 3 (3%) 
SHV detected from 100 E. coli isolates. The 18 phenotypically detected and E-test-positive strains (10 Klebsiella spp. 
and 8 E. coli) were retested with VITEK (GNS-532 card), and 17 of these strains (94.4%) were subsequently found to 
be ESBL positive. One strain (5.6%) tested ESBL negative by VITEK. The cefotaxime ESBL strip detected the presence 
of ESBL activity in these 18 phenotypically-positive strains.  
Discussion: The detection of ESBL-producing E. coli and Klebsiella isolates from Machakos District Hospital was 6%. 
The findings point out the need for continuous surveillance to determine prevalence of ESBL-producing 
Enterobacteria strains for better management of diarrheal illness. 
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1. Introduction 
Extended-spectrum beta-lactamases (ESBL) are 
enzymes that confer resistance to penicillins, third 
generation cephalosporins and aztreonam via 
hydrolysis of the antibiotics. These are inactivated by 
beta-lactamase inhibitors such as clavulanic acid 
(Paterson and Bonomo, 2005). Escherichia coli and K. 
pneumoniae are the most common ESBL producing 
bacterial species. However, ESBL has also been detected 
in other species of  Enterobacteriaceae and 
Pseudomonadaceae (Freitas et al, 2003). Infections due 
to ESBL-producing Enterobacteriaceae should not be 
treated with beta-lactam antibiotics due to the risks of 
therapeutic failure and increased infections that could 
result in death (Paterson and Bonomo, 2005). 
Production of ESBL enzymes  is an important 
mechanism of beta-lactam resistance in 
Enterobacteriaceae (Sanguinetti et al, 2003). Early 
detection of multiresistant bacteria is therefore vital 
indirecting treatment options  and isolation of patients, 
which is geared towards minimizing spread of these 
pathogens and also to prevent nosocomial  infections 
and outbreaks in the community (Paterson and 
Bonomo, 2005, Junior et al, 2004). The study aimed at 
evaluating the prevalence of ESBL producing E. coli and 
K. pneumoniae and to detect the presence of TEM and 
SHV genes among ESBL producing bacteria. The study 
enrolled subjects from all ages presenting to Machakos 
District Hospital for treatment of diarrhea. 
2. Methodology 
2.1 Patient recruitment 
Eligible for inclusion into the study were patients with 
three or more episodes of loose, watery, mucoid or 
bloody diarrhea in a day; those who had given consent 
to participate in the study and those who had not taken 
any antibiotic before visiting the hospital. The details of 
study was explained to the patient by the study nurse. 
Every third patient was recruited into the study after 
procurement of informed consent.  
2.2 Sample collection 
After the patient or guardian had been thoroughly 
briefed about the study and given signed consent to 
participate, the patient was given a sterile stool cup to 
collect a single stool sample. In case of a minor, the 
guardian or parent gave the consent. Care was taken 
during stool collection to avoid contamination with 
urine, soil or water. Part of the collected stool was 
transferred into Carry Blair transport medium and 
shipped to Kenya Medical Research Institute 
Microbiology laboratory for processing and 
identification. 
2.3 Bacteria identification:  
The stool samples upon arrival at the laboratory were 
macro examined, recorded and plated immediately on 
MacConkey for 18 to 24 h at 37°C. Five lactose 
fermenters and one mucoid colony from each 
MacConkey plate were sub cultured for purity on 
nutrient agar and then used for biochemical testing 
(Heuvelink et al 1995). The biochemical used were 
[triple sugar iron (TSI), motility, indole and ornithine 
(MIO), and Simmon’s citrate (SC)]… The positive results 
for positive E. coli were read as TSI: A/A, ± Gas and -
H2S. MIO: + motility, +indole, ±ornithine; Simmon’s 
citrate: negative.  K. pneuomonia was confirmed as TSI: 
A/A, + Gas and -H2S. MIO: + motility, +indole, 
+ornithine; Simmon’s citrate:positive.  
2.4 Antibiotic susceptibility testing 
Following identification the isolates were purified again 
on nutrient agar and tested for antimicrobial 
susceptibility including beta lactams, aminoglycosides, 
penicillins and quinolones. Antimicrobial susceptibility 
testing was carried out on 12 different antibiotics based 
on treatment of Clinical and Laboratory Standards 
Institute guidelines (CLSI, 2012). Those that were 
resistant to third genaration cephalosporins were 
tested for the presence of the extended spectrum beta 
lactamases using double disc diffusion (DDD), E-test, 
VITEK and finally PCR for detection of TEM and SHV 
resistance genes.  
The antibiotic susceptibility profiles were performed 
according to the Kirby-Bauer disk diffusion method and 
interpreted based on the CLSI guidelines (CLSI, 2012). 
Briefly: freshly prepared bacteria were emulsified into a 
normal saline standard suspension that was adjusted to 
equivalent turbidity to 0.5 McFarland standard. This 
was spread on freshly prepared and quality controlled 
Mueller Hinton agar and spread evenly using a curved 
rod. The 12 antibiotics were applied on the plate with 
bacteria using a disc dispenser and allowed to settle for 
10 minutes before incubating at 37 °C for 18-24 hours. 
Following incubation, the susceptibility results were 
read and interpreted based on CLSI standards (CLSI, 
2012) as resistant, intermediate or susceptible. 
E-test 
A bacteria suspension of equivalent turbidity to 0.5 
McFarland standard was spread on freshly prepared 
Mueller Hinton and spread evenly using a glass rod. 
Sterile E-strips embedded with different antibiotics 
were applied on the inoculated plate and pressed gently 
with sterile forceps onto the plate before incubating for 
18-24 hours. Following incubation, the plates were read 
and interpreted base on the CLSI standard (CLSI, 2012) 
as resistant, intermediate or susceptible. 
MicroScan 
For MicroScan, a 0.5 McFarland equivalent of purified 
bacteria suspension was placed in to the 96 well plate 
and incubated in the MicroScan automated 
microbiological system for 18-24 hours. The MicroScan 
automatically interpreted the susceptibility results and 
flagged all bacteria that had cephalosporin resistance.  
VITEC testing 
Each isolate tested using double disc diffusion and E-
test was confirmed by VITEK. The VITEK system with 
the ESBL test panel was contained in the NO45 card (all 
from BioMérieux). The panel had six wells containing 
cefepime at 1.0 μg/ml, cefotaxime at 0.5 μg/ml, and 
ceftazidime at 0.5 μg/ml, alone and in combination with 
CA (10, 4, and 4 μg/ml, respectively), and growth in 
each well was quantitatively assessed by means of an 
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optical scanner. The proportional reduction in growth 
in wells containing cephalosporin plus CA compared 
with those containing the cephalosporin alone was 
considered indicative of ESBL production. Quality 
control strains (E. coli ATCC 25922, E. coli ATCC 35218, 
K. pneumoniae ATCC 700603, and P. aeruginosa ATCC 
27853) were included in each run. 
2.5 Phenotypic detection of ESBL  
The DDD method employed four discs; cefotaxim (30 
µg), cefotaxim/clavulanate (10 µg), ceftazidime (30 µg) 
and ceftazidime/clavulanate (10 µg) disks (Oxoid) and 
interpreted according to the standards established by 
the Clinical and Laboratory Standards (CLSI). A broth 
culture of the test organism was adjusted to a 0·5 
McFarland standard and inoculated onto freshly made 
and quality controlled Mueller–Hinton agar (Oxoid: 
Basingstoke, UK). The combination discs and the 
corresponding standard cephalosporin discs were 
placed at a distance of (20mm) from each other on the 
plate. The plates were incubated at 37 °C for 18 hrs 
aerobically before the zone sizes were recorded. A 
positive result was indicated by a zone-size difference of 
≤5 mm diameter between the combination disc and the 
corresponding standard antibiotic disc with phantom 
development. Minimum Inhibitory concentrations were 
carried out using both E-test and the MicroScan where 
the detection in resistance of Cephalosporins were 
recorded and flagged for the presence of ESBL. For all 
ESBL detection methods, the known ESBL-producing E. 
coli strains SA1636 (TEM-3) and SA1652 (SHV-2) were 
used as positive controls. E. coli NCTC 10418 was used 
as a negative control.  
2.6 Genotypic detection of ESBL 
Purified colonies of ESBLs producing K. pneumonia and 
E. coli were suspended in TE buffer and their DNA 
extracted by boiling (van Soolingen et al, 1991). The 
SHV and TEM genes were detected as described 
previously (Kariuki et al, 2002, del Carmen Rodríguez et 
al, 2004) briefly, specific primers for the genes (forward 
primer 5´-TCAGCGAAAAACACCTTG -3´; Reverse primer 
5´-CCCGCAGATAAATCACCA -3´ for SHV gene; forward 
primer 5´-GAGTATTCAACATTTCCGTGTC -3´; reverse 
primer 5´-TAATCAGTGAGGCACCTATCTC -3´ for TEM 
gene) were used for PCR amplification that produced 
498 bp and 861 bp PCR products for SHV and TEM 
genes, respectively (Integrated DNA Technologies, Inc. 
Coralville, USA), as described by Paterson (Paterson, 
2000). The PCR mixture consisted of 10 pmol of each 
primers, 1 μl DNA sample (3 μg/μl), 1.5 mM MgCl2, 0.2 
mM each dNTP, and 5 u Taq DNA polymerase (Cinagen, 
Iran) in a total number of 50 μl of PCR reaction.  
Amplification of SHV and TEM genes was performed as 
follows: initial denaturation at 95 °C for 2 min and 35 
cycles of 1 min at 95 °C, 30 sec at 60 °C (annealing), 1 
min at 72 °C (extension) and five min at 72 °C for the 
final extension. The amplified product was submitted 
for electrophoresis in 2% agarose gel (BioRad) with 
ethidium bromide (Invitrogen) (0.5 μg/mL) for 1 hour 
(6 Volts/cm), and visualized under UV light and results 
documented. 
2.7 Ethical considerations 
Ethical approval for the study was granted by the Kenya 
Medical Research Institute - Ethical Review Committee 
(Ref. No.: SSC 989). 
3.  Results 
Patients Age distribution 
The study sampled a total of 300 patients from all ages 
ranging from three months and above. Majority of the 
patients were aged below 5 years (48.3%). Macroscopic 
examination of stool consistency showed that majority 
of the stool samples were watery in nature (48%). 
These findings are summarized in in Table 1.  
Table 1: Patient age distribution and stool sample 
appearance 
Age range (years) N (%) 
Below 5  145 (48.3%) 
6 - 10  17 (5.7%) 
11 - 15  11(3.7%) 
16  - 20  20(6.7%) 
21 - 25  36(12% ) 
Above 26 years 71 (23.6%) 
  
Stool appearance % 
Bloody  6% 
Bloody/mucoid 12% 
Mucoid 34% 
Watery 48% 
 
 
 Figure 1. Phantom phenomena development by cephalosporin resistant K. pneumonia and E. coli isolates  
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       Figure 2. Multiplex PCR amplification of K. pneumonia and E. coli TEM and SHV genes. 
 
Extended Spectrum Beta Lactamase testing 
Out of the 300 samples from the Machakos District 
Hospital tested, 18 (6%) were positive for ESBL 
production by double disk diffusion (DDD).  
The 18 DDD and E test-positive strains (3 Klebsiella spp 
and 15 E. coli) were retested with VITEK (GNS-532 
card), and 17 of these strains (94.4%) were 
subsequently found to be ESBL positive. One strain 
tested ESBL negative by VITEK.  
The cefotaxime ESBL strip detected the presence of 
ESBL activity in 18 of the isolates identified as positive 
for ESBL production by DDD. All the 18 isolates 
demonstrated phantom phenomena that indicated the 
presence of ESBL (Figure 1).  
From genotypic results, TEM was detected in higher 
percentage compared to SHV resistance genes. Majority 
of the isolates did not carry any of the two genes 
(Figure 2 and Table 2). 
 
   Table 2. Frequency of TEM and SHV genotypes from K. pneumonia and E. coli 
Organism No. tested 
PCR Results 
TEM+ve (%) TEM -ve (%) SHV+ve (%) SHV -ve (%) 
K . pneumonia 200 8 (4%) 192 (96%) 2 (1%) 198 (99%) 
E. coli 100 5 (5%) 95 (95%) 3 (3%) 97 (97(%) 
 
4. Discussion 
The correct detection of ESBL producing 
microorganisms is a challenge for the laboratories, 
requiring not only phenotypic tests but also genotypic 
tests for all genes associated with beta-lactamase 
production. According to the majority of 
epidemiological studies on ESBL, K. pneumoniae and E. 
coli are the most common species implicated in this 
type of resistance. In this study, K. pneumonia and E.  
coli were the only bacteria carrying detectable ESBL 
(Table 1). The results agreed with a study done in Rio 
Grande do Sul by Freitas and co-workers who observed 
that these two species were the most prevalent among 
ESBL producing microorganisms, confirming 
international multicenter studies (Luzzaro et al, 2006, 
Sanguinetti et al, 2003; Perilli et al, 2002; Wikler, 2006; 
CLSI, 2012). These results are important as K. 
pneumoniae is the most frequent gram-negative 
bacteria involved in nosocomial outbreaks (Tofteland et 
al, 2007; Freitas et al, 2003; Coque et al, 2002).  
TEM was the most prevalent as compared to SHV in the 
current study (Table 2), findings that agree with Freitas 
et al (2003). The prevalence of SHV was lower 
compared to other studies done around the world.  
The use of three distinct substrates in the combined 
disk tests increased the sensitivity of the tests (Figure 
2), and cefotaxime and cefpodoxime performed best, 
despite the occurrence of non-coincident results. 
Because of the elevated percentages of ESBL-producing 
E. coli presenting low minimum inhibitory 
concentrations (MIC) of ceftazidime, Tofteland et al 
(2002) recommended the use of cefpodoxime alone or a 
combination of cefotaxime and ceftazidime as preferred 
substrates for ESBL detection. From the current study, 
18 (6%) of the isolated bacterial strains exhibited beta 
lactamases enzyme activity that is responsible for 
resistance. Studies in Brazil and Iran reported high 
prevalence of 61% and 24% respectively (Oliveira et al, 
2010, Zaniani et al, 2012).  
For the past 40 years, Klebsiella spp and pathogenic E. 
coli that are resistant to aminoglycosides have been 
known to cause outbreaks of hospital-acquired infection 
(Peterson et al, 2004, Casewell and Phillips, 1981). The 
discovery of plasmid-mediated ESBL production by 
Klebsiella spp and E. coli, together with plasmid-
mediated aminoglycoside resistance, in the early 1980s 
(Vinué et al, 2009) signaled a major new problem with 
antibiotic resistance. In the current study, 6% of isolates 
(Klebsiella spp and E. coli) were found to be ESBL 
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positive. Many clinicians and other health care 
providers may be unaware of the problem of ESBL 
production by gram-negative bacilli resulting in 
inappropriate medication.  
In developed countries, information on resistance to 
vancomycin especially by E. faecium as indicator 
organism is readily available to clinicians in routine 
laboratory reports. However, there is no universally 
accepted applicable marker of the presence of ESBLs. 
Although resistance of K. pneumoniae to ceftazidime is a 
useful marker for presence of ESBLs, fewer than 50% of 
Klebsiella isolates reported in Kenya undergo testing for 
susceptibility to ceftazidime, a common practice in 
developing world (Kariuki et al, 2005). Moreover, some 
types of ESBL-producing organisms appear susceptible 
to ceftazidime according to standard methods, and 
ceftazidime resistance may be due to mechanisms other 
than ESBL production (Monnet et al, 1997). 
Unfortunately, many laboratories in Kenya as well as 
elsewhere in the world do not test for ESBL production 
(Paterson and Bonomo, 2005, Luzzaro et al, 2006).  
Awareness of ESBL production by K. pneumoniae and E. 
coli is clinically important. The implications in clinical 
settings are that in the absence of infection control 
measures, ESBL-producing organisms can readily pass 
horizontally from patient to patient. Reliable laboratory 
methods are now available (DDD, E-strip and VITEK) by 
which ESBL production can be detected by clinical 
microbiology laboratories. These methods, which have 
also been promoted by the CLSI (Monnet et al, 1997; 
CLSI, 2012),  rely on initial screening tests and follow-
up confirmatory tests. It is believed therefore that 
clinicians should not have to specifically request these 
tests; rather, all K. pneumoniae and E. coli isolates 
should undergo routine screening by clinical 
microbiology laboratories. Isolates suspected of 
producing ESBLs should not be reported as susceptible 
to third-generation cephalosporins or cefepime until 
follow-up confirmatory tests are performed.  
From this study, it has been shown that the VITEK 
system reported one false-positive detection of ESBL 
activity with one strain of E. coli. This strain of E. coli 
had been reported as positive by the DDD and E-strip 
methods. The best combination by use of E-strip was 
cefotaxime and ceftazidime. These results were 
contrary to Vinue et al (2008) findings. Although the 
percentage of false-positive E. coli ESBL strains was only 
5.6% it is still a concern that the strain was misreported 
as ESBL producer by E-strip and DDD antibiotic 
susceptibility to ß-lactam antibiotics. There appears to 
be no obvious reason for these results. It is, however, 
unlikely to arise from a technical error, as the VITEK is a 
highly standardized system. 
In reported studies, the DDD test was able to detect 
82% and 88 % of ESBL-positive strains, respectively 
(Thomson and Sanders, 1992) contrary to the findings 
from this study (100% and 94.4%). The limitations of 
this test have been described elsewhere (Vinué et al, 
2009; Thomson and Sanders, 1992; Bush, 1996). It has 
been reported that cepodoxime achieves a 100 % 
sensitivity rate in detecting ESBLs in tested isolates, 
cefotaxime 92 %, and ceftazidime 82 % (Appleton and 
Hall, 2000; Oliveira et al, 2010). In contrast, the results 
on isolates from the current study showed that 
cefotaxime was the most efficient combination for the 
detection of ESBLs, with a sensitivity rate of 100%; the 
values for cepodoxime and ceftazidime were 50 % and 
90%, respectively.  
The commercially available ESBL E-test strip is a 
quantitative technique, and is widely regarded as the 
‘gold standard’ for detection in clinical laboratories of 
ESBL production (Crowley, 2001; M'Zali et al, 2000). In 
this study, it detected 100 % of the test isolates and this 
was only possible when both cefotaxime and 
ceftazidime strips were used in conjunction and not 
with cefpodoxime.  As noted above, the ceftazidime E-
test strip was less sensitive when solely used; this could 
be due to the possibility that there were other 
ceftazidime-hydrolysing ß-lactamases in some strains 
that were not sensitive to clavulanic acid, which could 
have reduced the sensitivity of the test. Thus, E- tests 
with both cephalosporins are recommended; however, 
this makes the technique expensive, and most clinical 
laboratories in Kenya would only use it for confirmation 
rather than routine testing.  
It should be noted that in this study one E. coli was 
falsely reported as ESBL positive by the two methods. 
For all ESBL positive K. pneumoniae in this study, the 
VITEK test was accurate, but it should be noted that this 
study only included VITEK ESBL - positive strains by the 
other two methods, and was therefore not an evaluation 
of the VITEK ESBL test itself per se.  To the best of the 
author’s knowledge, this is the first report on ESBL in 
Kenya reported from isolates in stool samples. The 
other two documentations available on ESBL were from 
blood and urine (Kariuki et al, 2005, Kariuki et al, 
2000).  
5. Conclusion 
Due to the 6% prevalence of resistance to 
cephalosporins used in Machakos County and the 
confirmation of TEM and SHV resistance genes, their 
continued use may not be appropriate for the treatment 
of infections caused by pathogenic E. coli and Klebsiella 
spp. This may be one of the reasons for increased 
morbidity (12.2%). Other effective drugs should be 
identified and adopted for use on a regular basis. The 
data underlines the importance of regular antimicrobial 
surveillance in district hospital settings such as 
Machakos and other counties. Consequently, the 
required laboratory infrastructure and protocols for 
surveillance of resistance must be established, 
monitored, evaluated and sustained.  Since over-the-
counter sale of commonly used antibiotics without 
prescription is inferred as one of the contributing 
factors for the spread of resistance, the practice must be 
curtailed if the antibiotic arsenal available to physicians 
is to continue to be effective. 
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